HOME >> BIOLOGY >> NEWS
Palatin Technologies' PT-141 increases sexual behavior in female animals

Preclinical studies have demonstrated that PT-141 significantly enhances sexual behavior in female rodents.

Palatin Technologies, Inc. (AMEX: PTN) is developing PT-141 as an investigational treatment for male and female sexual dysfunction. Data from preclinical efficacy studies of PT-141 will be presented Saturday, October 27th, at the Female Sexual Function Forum (FSFF) Meeting in Boston, MA.

The studies were performed by Palatin scientists in collaboration with Concordia University in Montreal. Annette M. Shadiack, PhD, Director, Biological Research at Palatin, will present the results.

The studies objectives were to evaluate PT-141s ability to enhance sexual behavior in female rodents. The studies were designed to allow for the evaluation of PT-141s effect on a variety of normal precopulatory sexual behaviors that are used by female rodents to heighten sexual arousal in their male partners. Female animals given PT-141 showed a significant, dose-responsive increase in a variety of these precopulatory sexual behaviors and actively solicited sexual contact from the males. Importantly, PT-141 treatment increased the female rodents desire to copulate.

These data suggest that stimulation of melanocortin receptors in the brain by PT-141 selectively increased motivation for sexual activity in female rodents. The results indicate that PT-141 has potential to offer a unique treatment for women with desire disorders said Dr. Shadiack.

Perry Molinoff, M.D., Executive Vice President of Research & Development of Palatin said, We are very excited about these results, which, in combination with the positive safety results from our Phase 1 clinical study in men, provide the basis for advancing this investigational drug into Phase 2 efficacy trials in women with Female Sexual Dysfunction (FSD) early next year.

Palatin recently completed a Phase 1 safety trial with PT-141 in men that demonstrated a positive safety profile. PT-141 wa
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
26-Oct-2001


Page: 1 2 3

Related biology news :

1. AVAX Technologies M-Vax™ cancer vaccine extends five-year overall survival in patients with lymph node metastatic melanoma
2. AVAX Technologies O-Vax™ cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer
3. AVAX Technologies AC Vaccine™ improves relapse-free survival
4. AVAX Technologies M-Vax™ cancer vaccine induces T cell mediated immune reactions in patients with metastatic melanoma
5. USC study links historical increases in life span to lower childhood exposure to infection
6. Moderate alcohol consumption increases plasma levels of a protective hormone
7. Protease-inhibitor cocktail protects, increases anti-microbial action of promising new peptide
8. Breast self examination increases womens concerns but has no effect on mortality
9. Educational program increases some safety behaviors for older drivers
10. Placental malaria increases mother-to-child HIV transmission
11. NIEHS-funded researchers find low-level ozone increases respiratory risk of asthmatic children

Post Your Comments:
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... 2015-2019"  report to their offering. One ... technology. With continuous advances in technology, it is important ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately need to ... site key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security company, launches ... the frustration that comes with usernames, passwords and PINs – ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
(Date:1/22/2015)... Diagenode, Inc., a leading global provider ... complete solutions for epigenetics research, recently launched a ... need for manual processing. The new ChIPettor System ... histones or transcription factors and a semi-automated pipette ...
(Date:1/22/2015)... Mass. , Jan. 22, 2015   GenoSpace , a ... of tools to enable the broad use of genomic, imaging ... announced the appointment of Michelle Munson , CEO of ... director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, 2014 ... advancing patient care in critical areas, announced the closing of ... and warrants to purchase up to an aggregate 3,500,000 shares ... share and $.01 per warrant.  The warrants have a per ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn cases ... Syngenta, are in the process of being consolidated in a ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL No. ... Kansas. , Management of the Syngenta GMO corn multidistrict litigation ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
Cached News: